Trade DexCom, Inc. - DXCM CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.27 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Dexcom Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 103.92 |
Open* | 104.5 |
1-Year Change* | -74.25% |
Day's Range* | 104.48 - 106.71 |
52 wk Range | 66.89-154.52 |
Average Volume (10 days) | 2.44M |
Average Volume (3 months) | 59.24M |
Market Cap | 42.88B |
P/E Ratio | 207.35 |
Shares Outstanding | 386.26M |
Revenue | 2.79B |
EPS | 0.54 |
Dividend (Yield %) | N/A |
Beta | 1.15 |
Next Earnings Date | Feb 8, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jan 26, 2023 | 106.51 | 1.61 | 1.53% | 104.90 | 106.94 | 103.66 |
Jan 25, 2023 | 103.92 | 0.84 | 0.81% | 103.08 | 104.87 | 102.36 |
Jan 24, 2023 | 105.89 | 0.74 | 0.70% | 105.15 | 106.36 | 102.52 |
Jan 23, 2023 | 106.25 | -0.75 | -0.70% | 107.00 | 108.73 | 105.87 |
Jan 20, 2023 | 107.72 | 1.88 | 1.78% | 105.84 | 107.91 | 104.65 |
Jan 19, 2023 | 106.01 | 0.12 | 0.11% | 105.89 | 107.57 | 105.56 |
Jan 18, 2023 | 106.54 | -2.35 | -2.16% | 108.89 | 110.13 | 106.33 |
Jan 17, 2023 | 109.39 | 2.37 | 2.21% | 107.02 | 109.54 | 105.38 |
Jan 13, 2023 | 108.28 | 2.72 | 2.58% | 105.56 | 108.52 | 104.94 |
Jan 12, 2023 | 107.03 | 1.74 | 1.65% | 105.29 | 108.38 | 103.20 |
Jan 11, 2023 | 106.04 | -5.64 | -5.05% | 111.68 | 112.32 | 104.94 |
Jan 10, 2023 | 110.78 | 2.23 | 2.05% | 108.55 | 111.86 | 107.67 |
Jan 9, 2023 | 109.89 | -1.90 | -1.70% | 111.79 | 113.12 | 107.21 |
Jan 6, 2023 | 115.67 | 3.49 | 3.11% | 112.18 | 116.86 | 110.41 |
Jan 5, 2023 | 111.58 | -1.64 | -1.45% | 113.22 | 113.98 | 110.28 |
Jan 4, 2023 | 114.21 | -2.62 | -2.24% | 116.83 | 117.46 | 113.14 |
Jan 3, 2023 | 114.63 | 0.22 | 0.19% | 114.41 | 115.98 | 111.98 |
Dec 30, 2022 | 113.14 | 3.14 | 2.85% | 110.00 | 113.23 | 109.03 |
Dec 29, 2022 | 111.96 | 2.45 | 2.24% | 109.51 | 113.25 | 109.00 |
Dec 28, 2022 | 109.71 | 0.50 | 0.46% | 109.21 | 111.64 | 108.84 |
DexCom, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 573.3 | 718.5 | 1031.6 | 1476 | 1926.7 | 2448.5 |
Revenue | 573.3 | 718.5 | 1031.6 | 1476 | 1926.7 | 2448.5 |
Cost of Revenue, Total | 194.9 | 226.4 | 367.7 | 530.4 | 622.2 | 739.9 |
Gross Profit | 378.4 | 492.1 | 663.9 | 945.6 | 1304.5 | 1708.6 |
Total Operating Expense | 637.2 | 761 | 1217.9 | 1333.7 | 1633.1 | 2184.2 |
Selling/General/Admin. Expenses, Total | 286.2 | 349.2 | 432.8 | 515.7 | 620.7 | 810.5 |
Research & Development | 156.1 | 185.4 | 417.4 | 273.5 | 359.9 | 604.2 |
Operating Income | -63.9 | -42.5 | -186.3 | 142.3 | 293.6 | 264.3 |
Interest Income (Expense), Net Non-Operating | -0.3 | -9.5 | 59.8 | -38.1 | -68.6 | -90.4 |
Other, Net | -0.7 | 3.4 | ||||
Net Income Before Taxes | -64.9 | -48.6 | -126.5 | 104.2 | 225 | 173.9 |
Net Income After Taxes | -65.6 | 55.5 | -127.5 | 101.1 | 493.6 | 154.7 |
Net Income Before Extra. Items | -65.6 | 55.5 | -127.5 | 101.1 | 493.6 | 154.7 |
Net Income | -65.6 | -50.2 | -127.1 | 101.1 | 493.6 | 154.7 |
Income Available to Common Excl. Extra. Items | -65.6 | 55.5 | -127.5 | 101.1 | 493.6 | 154.7 |
Income Available to Common Incl. Extra. Items | -65.6 | -50.2 | -127.1 | 101.1 | 493.6 | 154.7 |
Diluted Net Income | -65.6 | -50.2 | -127.1 | 101.1 | 493.6 | 154.7 |
Diluted Weighted Average Shares | 334.4 | 345.2 | 352.8 | 369.2 | 390 | 400.4 |
Diluted EPS Excluding Extraordinary Items | -0.19617 | 0.16078 | -0.36139 | 0.27384 | 1.26564 | 0.38636 |
Dividends per Share - Common Stock Primary Issue | 0 | |||||
Diluted Normalized EPS | -0.19617 | 0.18149 | -0.35145 | 0.33848 | 1.33881 | 0.50656 |
Total Extraordinary Items | -105.7 | 0.4 | 0 | |||
Unusual Expense (Income) | 14.1 | 30.3 | 29.6 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 505 | 595.1 | 650.2 | 698.2 | 628.8 |
Revenue | 505 | 595.1 | 650.2 | 698.2 | 628.8 |
Cost of Revenue, Total | 161.1 | 178 | 203.3 | 197.5 | 230.7 |
Gross Profit | 343.9 | 417.1 | 446.9 | 500.7 | 398.1 |
Total Operating Expense | 459.1 | 494.1 | 532.7 | 698.3 | 587.5 |
Selling/General/Admin. Expenses, Total | 188.6 | 187 | 199.8 | 235.1 | 220.9 |
Research & Development | 109.4 | 129.1 | 128.8 | 236.9 | 135.9 |
Operating Income | 45.9 | 101 | 117.5 | -0.1 | 41.3 |
Interest Income (Expense), Net Non-Operating | -4.6 | -24.3 | -26.8 | -14.6 | -5.2 |
Net Income Before Taxes | 41.3 | 76.7 | 90.7 | -14.7 | 36.1 |
Net Income After Taxes | 56.5 | 62.9 | 70.9 | -19.4 | 97.3 |
Net Income Before Extra. Items | 56.5 | 62.9 | 70.9 | -19.4 | 97.3 |
Net Income | 56.5 | 62.9 | 70.9 | -19.4 | 97.3 |
Income Available to Common Excl. Extra. Items | 56.5 | 62.9 | 70.9 | -19.4 | 97.3 |
Income Available to Common Incl. Extra. Items | 56.5 | 62.9 | 70.9 | -19.4 | 97.3 |
Diluted Net Income | 56.5 | 62.9 | 70.9 | -19.4 | 97.3 |
Diluted Weighted Average Shares | 418.4 | 398.4 | 402 | 388 | 428.8 |
Diluted EPS Excluding Extraordinary Items | 0.13504 | 0.15788 | 0.17637 | -0.05 | 0.22691 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.13504 | 0.15788 | 0.17792 | -0.00175 | 0.22691 |
Unusual Expense (Income) | 0 | 0.8 | 28.8 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 280 | 744.7 | 1699.5 | 1969.4 | 3424.8 | 3684.4 |
Cash and Short Term Investments | 123.7 | 548.6 | 1385.6 | 1533.3 | 2707.7 | 2731.2 |
Cash & Equivalents | 94.5 | 441.5 | 1137 | 446.2 | 817.6 | 1052.6 |
Short Term Investments | 29.2 | 107.1 | 248.6 | 1087.1 | 1890.1 | 1678.6 |
Total Receivables, Net | 101.7 | 134.3 | 226.7 | 286.3 | 428.5 | 514.3 |
Accounts Receivable - Trade, Net | 101.7 | 134.3 | 226.7 | 286.3 | 428.5 | 514.3 |
Total Inventory | 45.4 | 45.2 | 70.7 | 119.8 | 234.7 | 357.3 |
Prepaid Expenses | 9.2 | 16.6 | 16.5 | 30 | 53.9 | 81.6 |
Total Assets | 402.8 | 904.1 | 1916 | 2395 | 4290.5 | 4933.3 |
Property/Plant/Equipment, Total - Net | 109.4 | 145.6 | 183.1 | 392.8 | 608.6 | 889.9 |
Property/Plant/Equipment, Total - Gross | 156.6 | 200.4 | 262.9 | 497.8 | 762.8 | 1121.4 |
Accumulated Depreciation, Total | -47.2 | -54.8 | -79.8 | -105 | -154.2 | -231.5 |
Goodwill, Net | 11.3 | 12.1 | 18.7 | 18.6 | 19.3 | 26.5 |
Intangibles, Net | 0.2 | 31.5 | ||||
Other Long Term Assets, Total | 1.9 | 1.7 | 14.7 | 14.2 | 237.8 | 301 |
Total Current Liabilities | 102.4 | 138.9 | 222.4 | 360.2 | 614.1 | 720.8 |
Accounts Payable | 24.5 | 46.7 | 75.5 | 102.3 | 163.3 | 189.4 |
Accrued Expenses | 77 | 89 | 144 | 255.6 | 439.8 | 514.3 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0.6 | 8.8 | |||
Other Current Liabilities, Total | 0.9 | 3.2 | 2.9 | 1.7 | 2.2 | 17.1 |
Total Liabilities | 119 | 484.7 | 1252.7 | 1512.4 | 2464 | 2891.2 |
Total Long Term Debt | 6 | 334.3 | 1017.6 | 1074.1 | 1721.2 | 2038.8 |
Long Term Debt | 0 | 327.6 | 1010.3 | 1059.7 | 1667.2 | 1981.8 |
Capital Lease Obligations | 6 | 6.7 | 7.3 | 14.4 | 54 | 57 |
Other Liabilities, Total | 10.6 | 11.5 | 12.7 | 78.1 | 128.7 | 125.7 |
Total Equity | 283.8 | 419.4 | 663.3 | 882.6 | 1826.5 | 2042.1 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 905.7 | 1093.7 | 1560.6 | 1675.9 | 2125.3 | 2109 |
Retained Earnings (Accumulated Deficit) | -621 | -671.8 | -798.9 | -695.7 | -202.1 | 138.7 |
Other Equity, Total | -1 | -2.6 | 1.5 | 2.3 | 3.2 | 0.5 |
Total Liabilities & Shareholders’ Equity | 402.8 | 904.1 | 1916 | 2395 | 4290.5 | 4933.3 |
Total Common Shares Outstanding | 338.4 | 348 | 360 | 366.4 | 384.4 | 388 |
Treasury Stock - Common | -100 | -100 | -100 | -206.2 | ||
Deferred Income Tax | 5.9 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 3445.1 | 3474.2 | 3656.2 | 3684.4 | 3746.6 |
Cash and Short Term Investments | 2632.6 | 2584.9 | 2697.9 | 2731.2 | 2688.2 |
Cash & Equivalents | 733.8 | 1158.8 | 1444.3 | 1052.6 | 716 |
Short Term Investments | 1898.8 | 1426.1 | 1253.6 | 1678.6 | 1972.2 |
Total Receivables, Net | 443.4 | 483.5 | 529.1 | 514.3 | 544.5 |
Accounts Receivable - Trade, Net | 443.4 | 483.5 | 529.1 | 514.3 | 544.5 |
Total Inventory | 289.7 | 319.3 | 351.3 | 357.3 | 342.2 |
Prepaid Expenses | 79.4 | 86.5 | 77.9 | 81.6 | 171.7 |
Total Assets | 4389.8 | 4503.8 | 4775.9 | 4933.3 | 5057 |
Property/Plant/Equipment, Total - Net | 688.7 | 770.8 | 833.5 | 889.9 | 938.8 |
Property/Plant/Equipment, Total - Gross | 860.7 | 957.6 | 1036.5 | 1121.4 | 1203.7 |
Accumulated Depreciation, Total | -172 | -186.8 | -203 | -231.5 | -264.9 |
Goodwill, Net | 18.9 | 19.1 | 23.9 | 26.5 | 26.6 |
Other Long Term Assets, Total | 237.1 | 239.7 | 238.9 | 301 | 313.6 |
Total Current Liabilities | 604.1 | 600.7 | 734.9 | 720.8 | 711.4 |
Accounts Payable | 152.2 | 165.9 | 210 | 189.4 | 150.1 |
Accrued Expenses | 450 | 433 | 522.6 | 514.3 | 558.6 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.9 | 1.8 | 2.3 | 17.1 | 2.7 |
Total Liabilities | 2486.6 | 2506.2 | 2639.8 | 2891.2 | 2867.7 |
Total Long Term Debt | 1743 | 1768.1 | 1761.3 | 2038.8 | 2027.5 |
Long Term Debt | 1688.8 | 1710.7 | 1703.5 | 1981.8 | 1965.9 |
Capital Lease Obligations | 54.2 | 57.4 | 57.8 | 57 | 61.6 |
Other Liabilities, Total | 139.5 | 137.4 | 143.6 | 125.7 | 122.7 |
Total Equity | 1903.2 | 1997.6 | 2136.1 | 2042.1 | 2189.3 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 2162 | 2193.6 | 2322.1 | 2109 | 1996.6 |
Retained Earnings (Accumulated Deficit) | -161.8 | -98.9 | -28 | 138.7 | 236 |
Treasury Stock - Common | -100 | -100 | -159.5 | -206.2 | -37.3 |
Other Equity, Total | 2.9 | 2.8 | 1.4 | 0.5 | -6.1 |
Total Liabilities & Shareholders’ Equity | 4389.8 | 4503.8 | 4775.9 | 4933.3 | 5057 |
Total Common Shares Outstanding | 386.8 | 386.8 | 387.6 | 388 | 392.4 |
Intangibles, Net | 23.4 | 31.5 | 31.4 | ||
Deferred Income Tax | 5.9 | 6.1 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | -65.6 | -50.2 | -127.1 | 101.1 | 493.6 | 154.7 |
Cash From Operating Activities | 56.2 | 92 | 123.2 | 314.5 | 475.6 | 442.5 |
Cash From Operating Activities | 15 | 16.1 | 29.1 | 48.7 | 67.1 | 102 |
Non-Cash Items | 113.1 | 123.5 | 262.1 | 158.6 | 213 | 322.7 |
Cash Taxes Paid | 0.1 | 1.4 | 2.3 | 4.8 | 3.6 | 16.8 |
Cash Interest Paid | 0.1 | 2.4 | 3.6 | 10.4 | 10.6 | 11.6 |
Changes in Working Capital | -6.3 | 2.6 | -40.9 | 6.1 | -20.8 | -132 |
Cash From Investing Activities | -55.9 | -144.4 | -139.8 | -1015.2 | -1018 | -216.1 |
Capital Expenditures | -55.7 | -66 | -67.1 | -180 | -199 | -389.2 |
Other Investing Cash Flow Items, Total | -0.2 | -78.4 | -72.7 | -835.2 | -819 | 173.1 |
Cash From Financing Activities | 8.1 | 399.1 | 710.4 | 10.7 | 912.1 | 10.4 |
Issuance (Retirement) of Stock, Net | 10.4 | 10.1 | 94.6 | 11.9 | 15.3 | 20.3 |
Issuance (Retirement) of Debt, Net | -2.3 | 389 | 617.7 | 0 | 906.2 | 0 |
Net Change in Cash | 8.4 | 347 | 695.6 | -690.7 | 371.8 | 235.4 |
Foreign Exchange Effects | 0.3 | 1.8 | -0.7 | 2.1 | -1.4 | |
Financing Cash Flow Items | -1.9 | -1.2 | -9.4 | -9.9 | ||
Deferred Taxes | -277.3 | -4.9 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 40.3 | 103.2 | 174.1 | 154.7 | 97.3 |
Cash From Operating Activities | 27.8 | 89.4 | 336.7 | 442.5 | 71 |
Cash From Operating Activities | 20.9 | 44.4 | 69.9 | 102 | 36.8 |
Deferred Taxes | -0.3 | 0.1 | 0.2 | -4.9 | 0.1 |
Non-Cash Items | 58.2 | 120.3 | 185.1 | 322.7 | 34.3 |
Changes in Working Capital | -91.3 | -178.6 | -92.6 | -132 | -97.5 |
Cash From Investing Activities | -112.2 | 251 | 280 | -216.1 | -411.8 |
Capital Expenditures | -99.7 | -200.9 | -309 | -389.2 | -101.6 |
Other Investing Cash Flow Items, Total | -12.5 | 451.9 | 589 | 173.1 | -310.2 |
Cash From Financing Activities | 0.8 | 0.4 | 11.2 | 10.4 | 5.3 |
Financing Cash Flow Items | -7.9 | -8.3 | -9.1 | -9.9 | -4.8 |
Issuance (Retirement) of Stock, Net | 8.7 | 8.7 | 20.3 | 20.3 | 10.1 |
Foreign Exchange Effects | -0.4 | 0.1 | -0.9 | -1.4 | -1 |
Net Change in Cash | -84 | 340.9 | 627 | 235.4 | -336.5 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 11.263 | 43504103 | 506655 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.6274 | 21736347 | -75610 | 2022-09-30 | LOW |
Baillie Gifford & Co. | Investment Advisor | 4.4796 | 17302885 | -802293 | 2022-12-31 | LOW |
Sands Capital Management, LLC | Investment Advisor | 4.3218 | 16693318 | -1208895 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.2437 | 16391712 | 156880 | 2022-09-30 | LOW |
Capital Research Global Investors | Investment Advisor | 2.7262 | 10530238 | 2847171 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 2.5609 | 9891601 | -119599 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.3422 | 9047009 | 3297715 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0751 | 8015184 | 192962 | 2022-09-30 | LOW |
Nuveen LLC | Pension Fund | 2.0577 | 7948042 | 209503 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 1.8817 | 7268168 | -646636 | 2022-09-30 | LOW |
Jennison Associates LLC | Investment Advisor/Hedge Fund | 1.7976 | 6943376 | -1620235 | 2022-09-30 | LOW |
ClearBridge Investments, LLC | Investment Advisor/Hedge Fund | 1.4004 | 5408974 | -298536 | 2022-09-30 | LOW |
Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.334 | 5152750 | -589239 | 2022-12-31 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 1.265 | 4886021 | -1210023 | 2022-09-30 | LOW |
William Blair & Company, L.L.C. (Research) | Research Firm | 1.1965 | 4621748 | 119780 | 2022-09-30 | LOW |
Voya Investment Management LLC | Investment Advisor/Hedge Fund | 1.1531 | 4454124 | 1510296 | 2022-09-30 | MED |
Capital World Investors | Investment Advisor | 0.9751 | 3766229 | 47344 | 2022-09-30 | LOW |
Macquarie Investment Management | Investment Advisor | 0.9446 | 3648714 | 374085 | 2022-09-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 0.8992 | 3473151 | -620387 | 2022-09-30 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
DexCom Company profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.Industry: | Medical Equipment, Supplies & Distribution (NEC) |
6340 Sequence Dr
SAN DIEGO
CALIFORNIA 92121
US
Income Statement
- Annual
- Quarterly
News

S&P 500, Nasdaq, DAX 40, Hang Seng technical update
Can the S&P 500 hold above its 2022 descending trend line?
12:44, 26 January 2023
Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending
AMZN Q4 earnings preview and technical analysis
09:59, 25 January 2023
Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike
Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.
15:49, 24 January 2023
Alphabet Q4 earnings: has google’s advertising revenue held up despite recession fears?
A preview of Google parent company Alphabet's fourth-quarter earnings after announcing its plans to cut 12,000 jobs.
11:47, 24 January 2023
FX Weekly Outlook: USD/JPY, EUR/USD Analysis
USD, USD/JPY, EUR/USD forecasts for the week ahead.
14:06, 20 January 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com